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Total skin electron irradiation (TSEI) for patients with cutaneous lymphomas is technically
challenging, and numerous approaches have been developed to overcome the many ﬁeld
matching problems associated with such a large and complex treatment volume. Since 1981
we  have delivered TSEI using a rotational total skin electron irradiation (RTSEI) technique
in  conjunction with patch, treat and boost ﬁelds in order to provide complete skin and
dose  coverage. Initially we used a 6 MeV electron beam at an extended source-skin distance
(SSD)  on a modiﬁed linear accelerator. More recently we began using a high dose rate elec-
tron mode on a commercially available linear accelerator. The RTSEI technique allows theMycosis fungoides
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delivery of a seamless surface dose to the majority of the patient’s skin surface in a single
treatment. In this review paper we present our three-decade experience with the technical
development, dosimetry, treatment delivery and clinical outcomes of our RTSEI technique.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
(TSEI) which may provide long-term disease control when1.  Background
Cutaneous T-cell and B-cell lymphomas are rare malignan-
cies that account for only 2% of all lymphomas. They are the
second most common site of extranodal non-Hodgkin’s lym-
phoma. Treatment of patients with cutaneous lymphomas is
challenging. There is no “ideal” or even standard treatment for
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1507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2013.05.002patients with more  extensive but still skin conﬁned disease,
and current recommendations and treatment guidelines typ-
ically suggest a number of possible options1,2 for treatment.
One of these options is total skin electron beam irradiation
3,4ll University Health Centre, 1650 Cedar Avenue, Montreal, QC, H3G
given alone or combined with adjuvant treatments with Pso-
ralen and ultra violet A (PUVA) or one of a variety of topical
or systemic agents.5 However, TSEI is technically difﬁcult and
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enerally not available even in large radiotherapy centers.
oreover it is also associated with acute and sub-acute side
ffects that may signiﬁcantly affect patients’ quality of life
uring and for several months post treatment. At the McGill
niversity Health Centre we have offered total skin electron
rradiation since the early 1980s using a rotational technique
hat was developed in-house. In total 172 patients have been
reated over the past 31 years. Our technique and clinical out-
omes have been described in detail elsewhere. The purpose
f this paper is to review the historical development of our
echnique, to discuss the technical challenges in setting up a
otal skin electron beam irradiation program, to explain some
f the practical details of treatment delivery, and to describe
cute and sub-acute side effects and care of the patients dur-
ng and after treatment. In addition, our goal is to share our
xperience at a time when it is more  feasible than in the past
o consider offering TSEI using a commercially available linac.
.  Technical  development  of  rotational  total
kin  electron  irradiation  (RTSEI)
ur original technique was custom developed on an exist-
ng linear accelerator (Clinac-18, Varian Medical Systems, Palo
lto, CA, USA) without TSEI capabilities.6–10 In order to reduce
he beam matching complications associated with deliver-
ng TSEI, an innovative technique delivering a large 6 MeV
lectron ﬁeld with the patient rotating within a stationary
lectron beam at an extended source-surface distance (SSD)
as developed. This technique is referred to as Rotational
otal Skin Electron Irradiation (RTSEI). The original technique
ating from 1981 is shown schematically in Fig. 1. During
reatment the patient stood on a rotating platform, at a nom-
nal SSD of 285 cm from the linear accelerator transmission
Fig. 1 – Schematic of the original RTSEI technitherapy 1 9 ( 2 0 1 4 ) 120–134 121
ionization chamber. The X-ray collimator was set to the max-
imum opening to give a 35 cm × 35 cm ﬁeld at 1 m from the
X-ray target and the collimator head was rotated to the 135◦
position in order to make the vertical dimension of the elec-
tron ﬁeld as large as possible. Both the X-ray target, which
was used in the 10 MV  X-ray mode, and the scattering foil,
which was used in the 6 MeV normal electron mode, were
removed so that the electron beam impinged directly onto the
transmission ionization chamber which thus served as the pri-
mary  electron beam scatterer. A custom-made scattering ﬁlter
was mounted on the machine accessory plate 35 cm from the
ionization chamber to both scatter and ﬂatten the electron
beam. A 4 ft × 8 ft sheet of Lucite of 1/4 in. (6 mm)  thickness
was placed 265 cm from the ionization chamber to further
scatter the electron beam and degrade its energy. The elec-
tron beam thus passed through the ionization chamber, the
custom-made scattering ﬁlter, and the Lucite scatterer before
it impinged upon the patient. Two external ionization cham-
bers were used for beam monitoring; both were mounted on
the Lucite scatterer. One was used to monitor the patient dose
and was placed on the horizontal ﬁeld central axis with the
sensitive volume about 20 cm from the ﬁeld center. The other
was used to monitor the beam ﬂatness and the dose rate, and
was placed 20 cm below the ﬁrst chamber. These two external
ionization chambers were critical to monitoring dose delivery,
since the geometry of the electron pencil beam rendered the
linac’s transmission ionization chamber unreliable.
For our original technique, beam parameters were charac-
terized in detail.6 Of particular interest were the vertical and
horizontal off-axis ratios, the percent depth dose and the abso-
lute dose and dose rate for both the stationary and the rotating
beam. In fact the beam itself was not rotating, so that the
reference to stationary and rotating electron beam refers to
the patient’s frame of reference. In addition, a considerable
que developed on the Varian Clinac-18.4
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Fig. 2 – PDD for the stationary and rotational original RTSEI
The electron output of the original RTSEI technique wastechnique. Inset shows the room geometry.5
amount of effort was invested into the understanding of the
complicated dosimetric effects of a patient rotating in a large
stationary electron beam, especially upon surface dose and
self shielding.8,9Fig. 2 shows the percent depth dose for the original RTSEI
technique. Previous TSEI techniques encountered difﬁculties
not only with beam matching, but also with the location of the
Fig. 3 – Off axis ratios of the original RTSEI technique in the vert
clinically unsuitable open beam is shown on the right (dashed liiotherapy 1 9 ( 2 0 1 4 ) 120–134
depth of maximum dose dmax. TSEI techniques aim to treat the
superﬁcial layer of the skin from the surface down  to a spec-
iﬁed depth. However, conventional stationary electron beams
exhibit a percent depth dose buildup region and dose fall off
that may not be desirable for TSEI. For example the percentage
depth dose PDD of a typical 6 MeV electron beam at an SSD
of 100 cm rises from about 78–100% over the ﬁrst 1.2 g/cm2,
and falls to 50% and 5% at about 2.3 g/cm2 and 3.0 g/cm2,
respectively. Multiple stationary beams may overlap and raise
the surface dose; however, as was found, and as shown in
Fig. 2, there is a marked improvement in the 6 MeV electron
beam PDD characteristics, ﬁrst for the stationary beam at an
extended SSD of 285 cm,  and subsequently when the patient
is rotating in the large ﬁeld at an extended SSD. Under con-
ditions of an extended SSD with the patient rotating in the
beam, the PDD rises to 100% at the surface, falls to 50% at
about 1.0–1.5 g/cm2 depending upon the presence of a Lucite
scatterer, and falls to about 5% at about 3.0 g/cm2.
The use of an empirically designed custom scattering ﬁl-
ter was important in producing a stationary electron beam at
extended SSD with clinically acceptable ﬂatness and symme-
try. Details of these beam characteristics are shown in Fig. 3.
In this ﬁgure the scatterer can be seen to produce a beam with
ﬂatness of ±5% over most of the ﬁeld and ±10% over the entire
region of clinical interest. For comparison, the consequence of
not having a custom-made scattering ﬁlter can be seen on the
right hand side of the sketch, with the open (unﬁltered) beam
clearly clinically unacceptable.about 60 cGy/min for the stationary beam at extended SSD.
The rotational surface dose was determined both experi-
mentally and analytically to be about 45% of the stationary
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iven dose. Thus, the rotational surface dose rate was about
5 cGy/min and typical treatment duration to deliver a tumor
ose of 250 cGy was of the order of 10 min.
Treatment time per fraction varied slightly because of
ccelerator output variations. The expected reading on the
xternal monitor chamber at the location of the Lucite plate
as pre-calculated to determine the appropriate treatment
ime. The individual treatment was terminated at the nearest
ull revolution of the platform just after the monitor cham-
er reached its required reading. This ensured that there were
lways an integer number of patient revolutions during the
eam-on time so that no body areas were over- or under-
osed. During successive treatment fractions the patient arm
ositions were cycled through two orientations (right arm up
r left arm up) and the patient feet positions were cycled
hrough three possible orientations. Thus, six possible combi-
ations of feet and arm locations were used so as to minimize
elf shielding. The patient used a rotating overhead handgrip
ttached to a chain in order to maintain balance through-
ut the 10-min rotation, and various combinations of eye and
ngernail/toenail shields were used according to physician’s
rescription. From 1981 to 2006 a total of 155 patients were
reated with our original RTSEI technique (see Fig. 4).
In 2005, an upgrade to our radiotherapy department
nvolved the decommissioning of the Varian Clinac-18 linear
ccelerator. In order to continue offering RTSEI treatments,
e transferred the technique to a modern Varian Clinac-21EX
ig. 4 – Distribution of patients treated with RTSEI from 1981 to 2
linac-18. 2005–2012: 17 patients treated with the Varian Clinac-therapy 1 9 ( 2 0 1 4 ) 120–134 123
(Varian Medical Systems, Palo Alto, CA, USA) linear acceler-
ator equipped with an optional high dose total skin electron
mode.11 This mode permits the delivery of a 6 MeV  electron
beam with a dose rate of the order of 27 Gy/min at an SSD
of 100 cm.  The 21EX linear accelerator is housed in a con-
ventional radiation therapy treatment bunker. The distance
from the isocenter (100 cm)  to the wall near where the patient
stands is greater than 300 cm,  allowing sufﬁcient space for
both the patient and the rotating platform. With the rotating
platform located a short distance from the wall, the treatment
SSD from the linear accelerator target to the patient’s umbili-
cus is 380 cm.  A photograph of the treatment room showing
the linear accelerator and the rotating platform is shown in
Fig. 5.
As with our original RTSEI technique, a very large ﬁeld, of
the order of 200 cm in height by 90 cm in width, is required to
cover the entire patient’s skin surface. Again, this is achieved
by rotating the gantry laterally to 270◦, the collimator to 45◦,
and the couch to 45◦. The precise couch position is not critical,
but it must be positioned such that it is out of the beam’s path.
The photon collimator jaws are opened to their largest avail-
able setting of 40 cm by 40 cm to provide the largest possible
ﬁeld size. The 6 MeV electron beam used in our current tech-
nique lacks sufﬁcient ﬂatness to be used clinically and so in a
manner similar to the original technique a custom-built ﬂat-
tening ﬁlter is added to the linac’s coded accessory tray. The
entire ﬁlter assembly is depicted in Fig. 6, with the left ﬁgure
012. 1992–2005: 155 patients treated with the Varian
21 EX.
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Fig. 5 – A photograph of the Clinac-21EX linac and
treatment room used for RTSEI since 2005. The linac and
couch positions, the rotating platform, the secondary
ionization chamber, and the patient supports (wall hand
try for the open beam are clinically unacceptable. The use ofgrip and overhead hanging handlebar).9
showing a schematic diagram of the ﬁlter and the right ﬁg-
ure showing a photograph of the ﬁlter mounted on the linac’s
accessory tray.
The original custom-built rotating platform with a 60 cm
diameter circular surface was retained for this current RTSEI
technique. Unmodiﬁed, the top surface is 30 cm above the
ﬂoor level. There is a hard foam spacer that can be added for
shorter patients in order to increase the platform’s height to
50 cm above the ﬂoor level. The platform has a small variable
speed motor: typically, 3 rpm is selected during patient treat-
ment. This setting is a compromise between the high speed
required to minimize the dosimetric dependence on start and
stop positions, and the low speed required for patient safety
and comfort. As with the original technique, a grip bar to
Fig. 6 – The custom-built ﬂattening ﬁlter constructed of aluminu
accessory tray. Left: a schematic diagram; right: a photograph of iotherapy 1 9 ( 2 0 1 4 ) 120–134
physically assist and support the patient is afﬁxed to the wall
to aid the patient during set-up, and a suspended rotating han-
dlebar is centered midline above the axis of rotation to help
the patient maintain balance during rotational treatment.
Given the extended SSD used in this technique, a higher
nominal output is required from the linear accelerator. This
is possible using the optional 6 MeV high dose rate elec-
tron mode provided by the manufacturer. Typically, in the
standard linac electron modes, the nominal output of the linac
is adjusted to yield 1 cGy per monitor unit (MU) at the depth of
maximum dose at 100 cm SSD. In the 6 MeV  high dose mode,
on the other hand, the linac yields about 3.1 cGy per MU  at the
depth of maximum dose at 100 cm SSD. Furthermore, in con-
trast with the conventional machine output of 600 MU/min,
the high dose rate electron mode runs at 888 MU/min. Conse-
quently, the nominal output of the linac at SSD 100 cm for the
6 MeV  high dose rate electron mode is approximately 2750 cGy
per minute as opposed to the nominal linac output of 600 cGy
per minute for the conventional 6 MeV electron mode.
Fig. 7 shows the standard 6 MeV PDD measured at an SSD
of 100 cm,  with a 10 cm by 10 cm electron applicator, along
with the stationary and rotational PDDs at an SSD of 380 cm
without applicator and with the custom-built ﬂattening ﬁlter
in place. In a similar manner to our original RTSEI technique
on the Clinac-18 machine, the combination of extended SSD
and patient rotation produce favorable beam characteristics
for RTSEI: the rotational PDD has a surface dose at 100%, and
an R50 of 1.5 g/cm2, and an Rp of 2.3 g/cm2. Of additional clini-
cal importance in total skin treatments is the bremsstrahlung
dose, as this represents the whole body dose that the patient
will receive during treatment. For our current technique on
the Clinac-21 EX the highest bremsstrahlung dose is delivered
at the central axis and is of the order of 2.7% at a depth of
5 g/cm2, similar to the original technique.
As in the original technique, beam ﬂatness and symme-an empirically designed ﬂattening ﬁlter, as shown in Fig. 6,
produces beam ﬂatness and symmetry at the extended treat-
ment SSD of 380 cm in both the vertical and the horizontal
m, lead, and PMMA  mounted on the Varian supplied
the ﬁlter mounted on the Varian-21EX linac service plate.9
reports of practical oncology and radio
Fig. 7 – PDD for the Clinac-21 EX 6 MeV  electron beam. The
stationary PDD measured at an SSD of 100 cm (open box),
the stationary PDD measured at an SSD of 380 cm (closed









r80 cm (solid line).9irections. The entire ﬁeld ﬂatness for the open ﬁeld and the
ltered ﬁeld can be seen by the isodose contour plots in Fig. 8.
he shaded body approximates the silhouette of an 80 kg man
ig. 8 – Beam contour plots, measured with and without the cus
 MeV  high dose electron− mode. The isodose contours represen
he shaded body approximates the silhouette of an 80 kg man  of
ight: the clinically acceptable ﬁltered beam.9therapy 1 9 ( 2 0 1 4 ) 120–134 125
of 180 cm in height. The poor dose ﬂatness in the unﬁltered
beam is shown on the left, the ﬁltered beam on the right. In the
case of the modiﬁed beam, we see that a typical patient would
be entirely covered by the 90% level and, except for forearms
and feet, would be irradiated to the 95% level.
Cross-sectional isodose distributions of the head, neck, and
abdomen have been measured for the full rotation technique
and are shown in Fig. 9. The absolute dose readings obtained
when a 200 cGy dose is delivered under RTSEI conditions are
shown.
The static beam calibration was carried out for our RTSEI
beam delivered with the gantry at 270◦, the collimator set
at 40 cm × 40 cm and rotated to 45◦, the couch at 45◦, the
custom ﬂattening ﬁlter in place, and a plane-parallel cham-
ber embedded in water equivalent phantom at the depth of
maximum dose. The details of the calibration procedure are
described in detail elsewhere.11 In this manner, the absorbed
dose delivered on the beam’s central axis at an SSD of 380 cm
per 1000 MU was determined to be about 54.0 cGy/1000 MU.
As in the original technique, a factor is required to relate
the dose rate at the surface of the rotating patient to the sta-
tionary dose rate. For our current technique the ratio of the two
dose rates was determined to be 0.448. This was in very closeoriginal RTSEI technique. Multiplying the stationary output of
54.0 cGy/1000 MU by the rotational factor of 0.45, results in the
rotational dose rate at the patient surface of 24.3 cGy/1000 MU.
tom-made scattering ﬁlter, at an SSD of 380 cm,  using the
t a percentage dose relative to the dose on the central axis.
 180 cm in height. Left: the clinically unsuitable open beam;
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Fig. 9 – Isodose plots of the head (left), and abdomen (right) measured in a humanoid phantom using the 6 MeV  RTSEI
olutetechnique to deliver a 200 cGy dose. Lines represent the abs
At the high dose mode dose rate of 888 MU/min, this results
in a treatment time of just shorter than 10 min, with about
28 revolutions, for a typical treatment fraction prescription
of 200 cGy delivered with 8230 MU. As for all other therapeu-
tic beams used at our institution, beam characteristics and
output are monitored by an external auditing agency.
Since the custom made ﬂattening ﬁlter is mounted down-
stream from the linac’s transmission ionization chamber,
there is a risk that treatment might be delivered without the
correct ﬁlter in place, or that the ﬁlter might break and fall
off during treatment resulting in a higher and non-uniform
treatment dose. As a precaution against this unlikely event,
a secondary dosimetry monitoring system consisting of an
independent ionization chamber and electrometer combina-
tion has been installed. The chamber is mounted on a support
system in the treatment beam slightly lateral to the patient
near the nominal treatment SSD of 380 cm.  During beam cal-
ibration, a relative factor is determined for this particular
set-up with the secondary dosimetry system, and in this man-
ner day-to-day treatments can be monitored for consistency
and to provide increased safety. This system also allows us to
carry out a set of pre-treatment checks prior to patient treat-
ment in order to ensure that the technique is ready for proper
beam delivery. The current technique has an additional advan-
tage over our original technique, in that it is delivered within
the scope of our current information management system
(ARIA, Varian Medical Systems, Palo Alto, CA, USA). Thus, it
can be scheduled, monitored, and recorded in the same man-
ner as all other patients in the clinic. From 2005 to 2012 a total
of 17 patients were treated with the RTSEI technique using the
Varian 21 EX (see Fig. 4).
3.  Clinical  considerations  and  beam
deliveryThe delivery of the TSEI requires the expertise of a TSEI treat-
ment team and close collaboration among the team members
comprised of radiation oncologists, medical physicists, and dose values in cGy measured using radiochromic ﬁlm.9
the treating therapists. Our RTSEI technique, as with all TSEI
techniques, leaves areas that are either completely untreated
or underdosed. In terms of treatment delivery, there are gener-
ally two distinct treatment sessions. One session is dedicated
to the delivery of the RTSEI component, and the second, to the
delivery of direct static electron ﬁelds to undosed regions (treat
ﬁelds), underdosed regions (patch ﬁelds), and regions requiring
supplemental dose (boost ﬁelds). These direct static ﬁelds are
delivered with the standard 6 MeV  (non high dose rate mode)
electron beam at the nominal SSD of 100 cm.  A description of
these considerations from the therapist’s perspective is pre-
sented here.
Following initial consultation and the decision to com-
mence total skin electron therapy, the patient is scheduled
in our mold room in order to prepare custom shielding and
accessories required for treatment. The patient also goes to
the treatment machine in order to simulate the position for the
RTSEI and perform planning for various direct electron ﬁelds
requiring custom-made cutouts. The length of the handlebar
that hangs from our treatment room ceiling is set according
to the height of the patient. The radiation oncologist and the-
rapists ensure that the patient is able to tolerate the rotating
motion of the platform, and the treating radiation oncologist
delineates the self-shielded areas requiring separate treat-
ment with direct electron ﬁelds with the patient in the RTSEI
treatment position.
All patients have eye shielding during RTSEI. This is prefer-
ably achieved using internal eye shields to ensure adequate
irradiation of any disease on the eyelids and around the orbits.
However, if there is no disease in the vicinity of the eyes, exter-
nal eye shields may be used instead of internal eye shields. In
our clinic, commercially available internal eye shields (Radia-
tion Products Design, Albertville, MN, USA) made of aluminum
and tungsten are available in 3 sizes in order to accommodate
the patient’s anatomy. External eye shields that are fabricated
in-house are constructed with oval pieces of lead that are cov-
ered in a layer of wax and are taped over the closed eyelids. We
have several different sizes and shapes of pre-made shields
that we can select in order to best conform to the patient’s










































the feet. The patient-side lead sheet hangs from the top of the
box and reaches to just above the patient’s ankles. The the-
rapists also have access to some malleable lead paste whichFig. 10 – The vertex shield (left) and a patient with the v
yes. Selected shields are labeled with the patient’s name
nd positional orientation and used throughout the patient’s
ourse of RTSEI treatment.
A “custom” vertex shield is chosen from an assortment of
llipse-like shapes of wax-covered lead. The purpose of the
ertex shield is to completely shield the top of the patient’s
ead during RTSEI treatment. Since it is very difﬁcult to esti-
ate the dose gradient being delivered to the slope between
he top of the head and the face of the patient, we aim to
liminate treatment to the larger part of the gradient during
TSEI and irradiate the vertex separately with a direct electron
reat ﬁeld. A vertex shield that best conforms to the patient’s
ead shape is ﬁrst chosen. Then a “halo”-like mark is drawn
n the patient’s scalp; this represents the area that requires
eparate treat irradiation and deﬁnes the location where the
herapist must position the shield on the patient’s vertex for
TSEI. This shield is identiﬁed with the patient’s name and
ositional orientation and used throughout the course of the
TSEI treatment. A photo of a vertex shield (left image) and
 patient with the vertex shield secured on his head (right
mage) for RTSEI treatment is shown in Fig. 10.
For irradiation of the separate vertex electron treat ﬁeld,
n open 25 cm × 25 cm cutout is used with a standard 6 MeV
tationary electron beam. The linac is setup with the gantry
t 270◦, collimator at 0◦, couch at 270◦ and the patient lying
upine, head toward gantry, with a cushion under the knees for
omfort. We  use a box made of Styrofoam that is covered with
 sheet of lead on the side that is facing the machine, and the
atient’s head lies on the posterior “headrest”-like Styrofoam
ase of this box. We  then appose two sheets of lead, each with
 half-circle cut in the middle, on the machine side of this box
n order to conform to the mark on the patient’s head, leaving
n open circle on the center area that requires treatment. Any
adiation outside this area falls on these pieces of ﬂexible lead
hen setup is done for this direct electron ﬁeld. The SSD for
he vertex ﬁeld treatment is 100 cm with 1 cm bolus so that
he SSD to the skin is 101 cm.  The sheet of bolus is secured to
he box and then taped again all around the exposed area in
rder to be in contact with the patient’s head. A photo of the
etup for vertex treatment is shown in Fig. 11.
For treat irradiation of the soles of the feet, an open
5 cm × 25 cm cutout is used with a standard 6 MeV electron
eam. The linac is setup with the gantry at 270◦, collimator at shield secured on his head (right) for RTSEI treatment.
0◦, couch at 270◦ with the patient lying supine with his feet
toward the gantry and a pillow under the head for comfort.
We again immobilize the patient using a box made of Styro-
foam that is covered with a sheet of lead on the side facing the
machine. The patient’s heels lie on the posterior Styrofoam
base of this box. On the day of planning, a malleable sheet
of lead is customized to the shape and size of the patient’s
feet so as to allow the soles of the feet to be exposed while
shielding the areas between, above and below completely. The
lead is cut so that when lying supine on the treatment bed,
the patient can point the toes and push through both “foot
holes” in the sheet of lead. The patient then pushes the heels
out and toes up so that the soles of the feet are upright and
just projecting out from the mold. This custom-cut sheet of
lead hangs from the top of the lead-lined Styrofoam box on
the side of the linac. The patient side of the box also has a
hanging full sheet of lead to counterbalance the weight of the
opposite side and to shield the patient from any radiation in
the case where there may be a small gap around one or both ofFig. 11 – The setup for direct ﬁeld treatment of the vertex.
The area irradiated corresponds to the area shielded by the
vertex shield in RTSEI shown in Fig. 10.
128  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 120–134
Fig. 12 – The setup for direct ﬁeld treatment of the soles of
the feet using the conventional 6 MeV  electron beam.
Set-up is at SSD 101 cm to the sole with 1 cm bolus (not
Fig. 13 – The setup for direct ﬁeld treatment of perineum.
Legs are supported by the linac “horseshoe” with a
Styrofoam spacer between the knees for comfort. Nominal
SSD to the skin is at SSD 101 cm with 1 cm bolus (not
supine with a cushion under their knees for comfort and bothshown).
can be pushed around the soles of the feet in order to shield
any gaps that may be leftover because of daily variations in
positioning and the rigidity of the sheet of lead around the
feet. Treatment is delivered in a similar manner to the vertex
at SSD 100–1 cm bolus. Therapists set up with SSD 101 cm to
the skin of one of the feet in an average depth area (not on the
arch or ball of the foot but somewhere in the middle). The the-
rapists must then displace the position of the treatment bed to
ensure that the ﬁeld light from the 25 cm × 25 cm cutout cov-
ers both soles of the feet completely while at the same time
the area irradiated around the feet must still fall within the
lead shielded area on the immobilization box. We then apply
1 cm bolus over the entirety of both soles. If the patient’s feet
are large, we  may modify the treatment technique in one of
two ways. If the feet are only slightly larger, we may be able
to obtain complete coverage of both soles by using the same
setup and simply using an extended SSD treatment distance.
In this case a measured output at the extended treatment SSD
is required. Alternatively, we  immobilize the patient’s feet in
the same way but use a custom made cutout to treat both feet
separately with individual treat ﬁelds. This cutout is basically
an oval shape centered within a 25 cm × 25 cm cutout, made
to be diagonal in orientation through the use of a 45◦ collima-
tor angle. A photo of the setup for direct ﬁeld treatment of the
feet is shown in Fig. 12.
In order to delineate the area around the perineum that is
self-shielded by the patient’s legs, we simulate RTSEI patient
positions in the 3 different foot positions and mark the com-
posite non-exposed area. The patient is then set up in a supine
position on the treatment couch, head on a pillow with but-
tocks on the very end of the couch near the linac. The patient’s
legs are positioned either in stirrups that can be ﬁxed to the
couch side rails or with legs up and feet and heels resting on
the horseshoe, knees bent and maintained at a reproducible
distance from each other with a Styrofoam block inserted
between the legs. Either of these positions allows reaching the
patient’s perineal area with an electron cone in place. At theshown).
time of planning, the marks delineating the self-shielded area
are simply connected to set the limits of the perineum direct
electron treat ﬁeld. The projection of this mark is drawn onto
a Plexiglas template inserted into a frame in an appropriately
sized electron cone (typically a 15 cm × 15 cm cone) with the
patient in treatment position. A custom cutout is required for
these ﬁelds for all patients. A direct 6 MeV electron beam is
used, with 1 cm bolus. As for other direct ﬁelds, setup is done
at SSD 100 cm to bolus. The conditions for direct ﬁeld treat-
ment of the perineum are shown in Figs. 13 (setup) and 14
(area irradiated).
The patient’s axillae usually require separate irradiation
through patch ﬁelds. This is because each axilla receives only
half of the RTSEI dose since the patient always has one
arm down during treatment, resulting in self-shielding. Delin-
eation of the area to be treated separately through a patch ﬁeld
is done by simulating RTSEI with both arm positions. The radi-
ation oncologist determines the limits of the axillae area to
be patch treated. Once these ﬁeld limits have been marked
on both sides, the patient is set up on the treatment couch,arms up using either a wingboard, or with hands clasped above
head so as to increase the ease of access to the axilla with the
electron cone. The projection of these marks is then used to
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 120–134 129




























Fig. 15 – Typical setup for direct ﬁeld patch of the axilla.
Limits of the ﬁeld to be patched are determined by the
radiation oncologist with the patient standing on the
due to self-shielding are the infra-mammary folds under pen-
dulous breasts and/or under a lower abdominal fold in obese
patients. These areas are veriﬁed by the radiation oncologistreatment of the perineum.
ake custom cutouts for these ﬁelds for both the right and
eft sides. The position of the treatment couch, the gantry and
he collimator is variable from patient to patient in order to
ave the incident electron beam as perpendicular as possible
o the area to be treated. Extended SSD setups are sometimes
ecessary for larger ﬁelds or with patients that have limited
rm mobility. 6 MeV  electrons are used, typically at SSD 100 cm
ith 1 cm bolus. A photo of the setup for direct ﬁeld patch of
he axilla is shown in Fig. 15.
The palms of patient’s hands require separate patch irra-
iation since the RTSEI delivery contributes only half the
rescription dose given that the hand holding onto the han-
lebar is shielded. The other hand is at the patient’s side, and
pen. We  treat the palms of the hands using a 6 MeV electron
eam and an open standard 25 cm × 25 cm cutout. The linac
s setup with the gantry at 180◦, collimator at 0◦ and couch
t 0◦. We  use a see-through tabletop that allows the thera-
ist to see the ﬁeld light. The patient is treated in a standing
osition by aligning the limit of the palm of the hands that is
xposed while holding the handlebar. This limit is delineated
ith a mark drawn by the treating therapist when the patient
s holding onto the handlebar during RTSEI. We  then ensure
hat both hands are within the irradiated area and that the
ands lie ﬂat on a 1 cm thick bolus with SSD set to 100 cm at
he bolus. An additional 1 cm of bolus for backscatter is placed
n the exit side of the patient’s hands. A photo of the setup
or direct ﬁeld patch of the hands is shown in Fig. 16.platform, in the RTSEI position.
Other areas that may require separate patch ﬁeld irradiationFig. 16 – Setup for direct ﬁeld patch of the hands. Hands are
typically placed upon a 1 cm slab of bolus, with an
additional 1 cm of bolus for backscatter.
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fungoides when TSEI is the sole treatment is 36 Gy given in 18Fig. 17 – Typical setup for shielding the ﬁngernails.
at the time of planning with the patient in RTSEI treatment
position, and treatment ﬁeld limits are deﬁned if deemed nec-
essary. Any patch treatment to these areas is usually delivered
with a 6 MeV  electron beam through a custom cutout that is
made for the patient, in a treatment position that allows for
reproducibility and accessibility to area, and is as parallel as
possible to the electron cone. Bolus is used as required.
Shielding of the nails is considered an option for patients
with no disease distal to the elbows and/or knees. Over the
years we  have assembled a large variety of shapes and sizes of
nail shields, and similarly to the in-house external eye shields
they are small round or oval pieces of lead covered in wax. A
photo of the shielding technique for ﬁngernails is shown in
Fig. 17.
Prior to delivery of the RTSEI component of the treatment
regime the therapists prepare the treatment room. The treat-
ment couch is moved out of the way, to 45◦, and the gantry is
rotated to the lateral (270◦) facing the rotating platform. The
RTSEI ﬁlter is inserted into the collimator angled to 45◦, and the
ﬁeld size is set to its maximum of 40 cm × 40 cm automatically
after detecting the presence of the ﬁlter.
Our procedure currently involves a pre-treatment mea-
surement of the dose delivered with our RTSEI beam. Once
all pre-treatment checks have been performed, the therapists
can proceed with the RTSEI patient preparations.
The therapists begin by assembling the eye shielding, the
vertex shield, and any necessary nail shielding. The patient
removes all clothing including underwear and changes into a
thin, disposable paper hospital gown  (originally intended for
isolation patients), the sleeves of which have been cut off. The
dosimetric effect of this gown has been determined to be neg-
ligible, and this gown  provides the patient some measure of
comfort and dignity during the treatment procedure.
The patient sits down for ﬁnal preparation before assuming
treatment positions. Toe and ﬁnger nail shields are taped and
secured in place according to the physician’s prescription.
A chair is setup inside the treatment room where technol-
ogists secure the vertex shield on top of the patient’s head,
and the eye shielding. External eye shields can be simply
taped over the patient’s closed eyes and secured into placeiotherapy 1 9 ( 2 0 1 4 ) 120–134
with a mesh-like stretchy dressing that wraps around the
patient’s head and over the eyes. In patients requiring the
use of internal eye shields the therapist ﬁrst anaesthetizes the
patient’s eyes using xylocaine eye drops. This usually requires
about 3 drops to each eye. By the time the third drop goes
into the eye the pupil no longer reacts, which generally indi-
cates that the eye shield can be safely and painlessly inserted.
Once the internal eye shields are inserted into the eyes, the
eyes are taped shut. The same mesh-like dressing is wrapped
around the patient’s head and over the eyes. Once the eyes
are shielded, the vertex shield is positioned on the patient’s
head and secured into place with the mesh-like dressing that
covers the top of the head and passes under the chin (Fig. 10).
Once prepared, the patient is helped onto the platform and
one of the six available arm and feet combinations is cho-
sen. The patient’s chin is up, the patient’s free arm is down
and slightly away from body with elbow slightly bent and
palm open. The rotating platform motor is set to 3 RPM, and
patient balance and clearance from wall with arm is ensured.
A physicist is present along with the therapist during delivery
of the RTSEI treatment. A photo of the patient ready for RTSEI
treatment is shown in Fig. 19, and the custom built rotating
platform with the three color-coded feet position locations is
shown in Fig. 20. RTSEI treatment is commenced once all staff
have left the treatment room. The patient is monitored during
treatment with intercom and closed circuit TV.
Occasionally we treat patients with reduced mobility who
are unable to tolerate the rotational nature of RTSEI. These
patients are setup in a manner similar to other patients in
terms of vertex, eye and ﬁngernail shields. They are assisted
to stand on the platform and a four-legged walker is placed
on the platform in order to afford the patient more  stability.
The patient is rotated to six positions by having the platform
rotate and then stop at every 60 degrees. At each of the six
stop positions, the therapists leave the treatment room and
deliver one sixth of the calculated MUs. The therapists then re-
enter the treatment room and rotate the platform by another
60 degrees, leave the room and deliver another set of MUs,
until the entire MU set has been delivered.
Another modiﬁcation to the standard RTSEI delivery is
encountered when patients only require a portion of their
body to be treated. Sometimes upper body only, lower body
only or head only are treated. A large sheet of plywood,
two inches thick and suspended from the ceiling is used to
delineate the treatment volume. The output for these RTSEI
treatments are determined for each patient depending upon
the location of the wood shield. Interestingly, we have noted
that patients receiving lower body irradiation, having the
upper part of their body shielded, become dizzy during RTSEI
without the presence of eye shields. Thus, all patients have
external eye shields, even when this is not clinically necessary.
4.  Dose  prescription
A typical dose prescription for a RTSEI patient with mycosisor 20 fractions of 1.8 or 2 Gy given 4 days each week. Untreated
areas (treat volumes) are treated to a similar dose, while the
prescribed dose to areas underdosed because of self-shielding
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Fig. 18 – Typical ﬁeld delineation for direct ﬁeld boost of the



































Fig. 19 – A photo of the patient ready for RTSEI treatment.
The patient is standing on the rotating platform and is able
to support himself with the rotating hand grip above his
head. Note the presence of the vertex shield, eye shields,
the arm and leg positions. The secondary ionization
chamber used to monitor the beam may also be seen at thencologist.
patch volumes) is typically half of that dose, namely 18 Gy
iven in 9 or 10 fractions of 1.8 or 2 Gy given on 2 days each
eek.
Thicker lesions or tumors in patients with more  advanced
isease may require treatment with boost ﬁelds (Fig. 18). This
s usually given prior to RTSEI so that all disease at the time
f start of RTSEI will be within the range of penetration of
he electron beam. Treatment is delivered usually with direct
lectron ﬁelds but sometimes with photons to low doses such
s 15 Gy in 5 daily fractions, depending on the depth and extent
f the lesion(s).
Patients are typically given RTSEI treatments on Monday,
uesday, Thursday and Friday. Boost, patch and treat ﬁelds to
he vertex, soles and palms, perineum, inframammary folds
nd elsewhere are delivered as required throughout the ﬁve
eekdays.
.  Care  before,  during,  and  after  TSEI
SEI is a difﬁcult treatment for some, but not all, patients.
atients need to be prepared well for treatment, and prepara-
ion usually takes at least two visits to the radiation oncology
epartment. The ﬁrst visit includes the consultation and dis-
ussion of treatment options with the radiation oncologist and
he second involves a session with a specialist therapist who
hows the patient the treatment unit and explains the various
spects of treatment. Patients are allowed to shower and told
hat they can use a hydrating cream as is our standard practice
or treatment to other areas. During treatment, patients are
valuated weekly initially. By week 3 many  will have some
rythema of the skin and by week 4 some may need spe-
ial creams such as ﬂamazine. By week 4 patients may have
ome swelling of the extremities. If swelling is severe and/or
here is blistering (usually the feet, less frequently the hands)
onsideration is given to discontinuing the boosts to the
oles of the feet at this point. Blood counts are monitored
eekly during TSEI although unless patients have receivedlevel of the waist, mounted on the Lexite sheet.
prior chemotherapy it is unusual to see any signiﬁcant change
during treatment and very rare indeed to have to interrupt
treatment.
Patients are followed very closely (Q 2–3 months) following
treatment. Once the acute skin reaction and any edema has
settled down (typically within the ﬁrst 4–6 weeks) the degree
of response is reasonably evident. However, sometimes there
are residual lesions that if still present 6–9 months post TSEI
should be biopsied and if positive can be boosted with local,
low dose, radiotherapy with a good probability of permanent
control.
6.  Clinical  outcomesClinical outcomes using our original RTSEI technique have
been published twice previously.12,13 Fig. 21 shows cause-
speciﬁc survival and Fig. 22 shows cause-speciﬁc survival by
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Fig. 20 – The custom built rotating platform with the three
Fig. 22 – Cause-speciﬁc survival by T stage at RTSEI as
reported by Freeman et al.12
Fig. 23 – Overall survival as reported by Roberge et al.13
Patients with mycosis fungoides were  treated either withcolor-coded feet locations. A variable speed regulator is
seen at the left of the platform.
T stage as reported by Freeman et al.12 in 1992. Fig. 23 shows
overall survival and Fig. 24 shows freedom from recurrence in
complete responders as reported by Roberge et al.13
At each review, acute toxicity was considered acceptable.
Longer term sequelae were limited to permanent hair loss in a
band-like distribution at the junction of the vertex and RTSEI
ﬁelds in some patients, and dry skin and brittle nails which
is a more  universal ﬁnding. Telangectasia, which is common
in patients treated with TSEI techniques using multiple sta-
tionary ﬁelds, is infrequently seen. Response to RTSEI was
good, with a complete response rate of 73% in the 44 patients
included in the 1992 review and 65% of the 31 patients treated
with RTSEI alone included in the 2007 review. Overall 5-year
survival was 38% and 50% respectively. In both reviews, long
term relapse-free and overall survival were better for patients
with earlier stage (T2, stages IA–IIa) disease than for more
advanced disease.
Fig. 21 – Cause-speciﬁc survival for 44 patients with
mycosis fungoides treated with RTSEI as reported by
Freeman et al.12RTSEI (TSEI) alone or RTSEI and alpha-interferon (IFN).
Early results are quite similar for the patients treated
since 2005 using our current technique (Table 1). A somewhat
larger percentage (4/17) of patients treated since 2005 have
diseases other than mycosis fungoides/CTCL and three of
these received only low dose RTSEI (4–12 Gy in 2–5 fractions).
Fig. 24 – Freedom from recurrence in complete responders
as reported by Roberge et al.13
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Table 1 – Characteristics of 17 patients treated with current RTSEI technique.
Age/sex Diagnosis/stage Prior/local RT Dose/fx Side effects Response
77/F NHL blastic NK-cell type No 30 Gy/15 fx Hematologic toxicity GPR
43/M CTCL CD8+ Yes 36 Gy/18 fx Gr 3 dermatitis, blistering of
hands and feet
GPR
72/M Follicular lymphoma No 30.6 Gy/17 fx None CR
75/M MF stage IIB T3 N1 Yes 24 Gy/12 fx Gr 3 dermatitis, swelling
and blistering of hands and
feet. Discontinued RTSEI
early b/c of toxicity
CR
74/M CTCL, non MF No 32 Gy/16 fx Gr 3 dermatitis CR
64/M MF stage IIB T3 N0 No 16 Gy/8 fx None. Discontinued RTSEI
early b/c of deteriorating
general condition
NR
68/M CLL No 4 Gy/2 fx None PD
73/M MF stage IVA T4 N3 No 36 Gy/20 fx Pain and swelling of feet NR
67/F MF stage IIA T2 N1 No 36 Gy/18 fx Gr 2 dermatitis GPR
70/F MF stage IA T1 N0 No 36 Gy/18 fx Gr 2 dermatitis, swelling of
hands and feet
Unknown, no follow up
81/M AML, lymphoma cutis No 12 Gy/5 fx None Unknown, no follow up
43/F HTLV-1 T-cell lymphoma No 5 Gy/2 fx None NR
69/F CTCL Yes 29 Gy/15 fx Gr 2 dermatitis GPR
69/F MALT lymphoma Yes 12 Gy/3 fx None
66/M MF stage IIB T3 N0 Yes 36 Gy/18 fx Gr 3 dermatitis, swelling of
hands and feet
CR
25/F MF stage IIB T3 Nx Yes 30.6 Gy/17 fx Gr 2 dermatitis CR






























rGPR: good partial response, CR: complete response, NR no response, 
f the 12 patients (10 with mycosis fungoides/CTCL, one with
 non-Hodgkin lymphoma blastic NK-cell type and one with a
ollicular lymphoma) that received RTSEI to doses ≥24 Gy, 9/12
ad grade 2 or 3 dermatitis and 6/12 had swelling of the feet
nd/or hands, and treatment was discontinued at an RTSEI
ose lower than planned in one of these patients because of
his. Only one patient developed hematologic toxicity. She had
een treated prior to RTSEI with chemotherapy and soon post
TSEI was found to have bone marrow involvement. Of the
 patients with mycosis fungoides who received RTSEI to a
ose ≥24 Gy, 5/7 of whom had advanced stage (≥IIB) disease, a
omplete response was seen by the end of treatment in four
nd a good partial response in one. Only one patient, a patient
ith stage IVA T4 N3 mycosis fungoides, showed essentially
o response to treatment by completion of treatment. For one
f these 7 patients, no information regarding response to treat-
ent was available.
.  Conclusions
e  have seen a ﬂuctuation in the numbers of patients with
ycosis fungoides referred for TSEI over the years as new top-
cal and systemic agents have become available for treatment.
owever, as we  and others have shown, TSEI is a useful treat-
ent for this difﬁcult disease, with a high complete response
ate even in patients with advanced disease. Adjuvant treat-
ent may be required to maintain response and an “ideal”
anagement strategy has not yet been established.
TSEI is technically challenging due to the complex volume
equiring treatment, and ﬁeld matching remains the primary
ource of difﬁculty. At the McGill University Health Centrehands and feet
rogressive disease.
our 6 MeV rotational total skin electron irradiation technique
(RTSEI) at an extended SSD seamlessly delivers a total skin
dose while avoiding most of the beam matching problems
associated with static electron ﬁeld delivery. From 1981 to
2012, 172 patients have been treated, originally using a modi-
ﬁed linear accelerator, and currently using a linear accelerator
with a commercially available high dose electron mode. The
dynamic nature of the RTSEI treatment has unique dosimetric
aspects associated with the beam energy (PDD), beam ﬂatness
and absolute output. The treatment requires the close collabo-
ration of radiation oncologists, treating therapists and medical
physicists to deliver the RTSEI component of the treatment
along with treat, patch, and boost ﬁelds to ensure complete
volume and dose coverage.
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